About Us

Since its creation in 1986, NeoMPS SA has been in perpetual evolution, consistently adapting operations to meet the always expanding needs of its customers.

NeoMPS SA has supplied over 35.000 different products in milligram to gram quantities to the scientific community, acquiring a great deal of expertise in the manufacture of unusual amino acids, peptides and peptide derivatives.

In 1998, our GMP production facility became fully functional enabling us to supply hundreds of grams to kilogram quantities of Active Pharmaceutical Ingredients (APIs) to biopharmaceutical companies around the world.

From the beginning, our goal at NeoMPS SA is to provide a full spectrum of technologies of products and services. We offer custom peptide synthesis for research and development, amino acids, peptide building blocks, custom organic synthesis and GMP manufacturing.

Nearly one thousand regular customers worlwide trust our company and can attest to our reliability. This is the result of good technology placed in well-qualified hands enhanced by the dedication our people bring to their work.

Now with two facilities on two different continents: NeoMPS, Inc. in California, USA, and NeoMPS SA in France are united to serve you with separate geographical distributions and complementary capabilities.

Development stages

1986	NEOSYSTEM is founded
1992	NEOSYSTEM becomes a subsidiary of GROUPE SNPE
1997	Construction of the new production unit (800 sq.m)
2001 2002	NEOSYSTEM acquires MPS Staff: 35     Turnover: 6 Million USD 7 million US Dollar investment in a new building 4.500 sq.m in San Diego.
2003	MPS+ NEOSYSTEM : Staff : 95 Turnover : 17 million USD
2004	Neosystem and Multiple Peptide Systems (MPS) decide to reinforce their union and use a common name : NeoMPS Neosystem becomes NeoMPS SA and MPS becomes NeoMPS, Inc. - 6.300 sq. m (Strasbourg+San Diego).

2006 Turnover: 19 million USD

2007 Project of building 2.400 sq.m new facility to increase capacity in Strasbourg.

2007 NeoMPS has become part of the PolyPeptide Laboratories Group.

Key figures NeoMPS SA

- Over 1.000 regular customers
- 64% of our turnover from exportation
- 90% of our turnover from pharmaceutical companies
- in number of customers: 60% private sector, 40 % public sector
- Close to 37.000 original molecules produced
- Currently 2.000 to 2.500 new molecules synthesized each year
- About 40 products are in pharmaceutical development, phases I-III: 2 DMF accepted, 1 under submission.
- Inspection from the French Health Products Safety Agency (AFSSAPS) in May 2006, GMP compliance certificate obtained in September 2006.

NeoMPS team, Strasbourg